Research Grade Dusigitumab

Catalog No.

DHC12002

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG2-nd

Clonality

Monoclonal

Target

IGF-I, IGF1, Mechano growth factor, MGF, Insulin-like growth factor I, IBP1, Somatomedin-C, IGF2, IGF-II, Insulin-like growth factor II, T3M-11-derived growth factor, Somatomedin-A

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P05019 & P01344

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MEDI-573, CAS: 1204390-13-5

Clone ID

Dusigitumab

MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas, PMID: 25193511

Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours, PMID: 25342141

Integrated analysis and clinical correlation analysis of hub genes, immune infiltration, and potential therapeutic agents related to lupus nephritis., PMID:36912500

Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours., PMID:25342141

MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas., PMID:25193511

Document Download

Research Grade Dusigitumab.pdf